Description
Created On: 2020-07-15
Record Count: 19
Primary Industries
- Drugs
- Cancer
- Disease
- Therapeutic
- Diagnostic
- DNA
- Assay
- Drug Discovery
- Research
- Skin care
- Pharmaceuticals
- Diabetes Treatment
- obesity
- Fibrosis
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 266760
The Licensed Compound shall means PND-1186 and/or PND-1188; any metabolites or prodrugs of PND-1186 and/or PND-1188; any hydrates, conjugates, salts, esters, isomers, polymorphs or analogues of the foregoing; and any other compounds that are Covered by a Licensed Patent Right and have as a primary mode of action the inhibition of FAK.
The patents are for Inhibitors of Focal Adhesion Kinase; Synthesis and use of Kinase Inhibitors; and oral formulation of Kinase Inhibitors.
Licensee is engaged in research and development of pharmaceutical products for the treatment of cancer.
IPSCIO Record ID: 233451
The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.
The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.
The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.
Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.
IPSCIO Record ID: 243433
The patent is for Substituted Indazole Derivatives Active as Kinase Inhibitors.
RXDX-103 is an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase, and RXDX-104 is a program to identify a highly selective inhibitor of the rearranged during transfection (RET) tyrosine kinase. Each of these programs is in preclinical development for the potential treatment of multiple cancers.
Loss of cell cycle control is a hallmark of cancer, and interfering with the DNA replication process is a proven strategy for cancer therapy. Currently available chemotherapies, such as anti-metabolites, topoisomerase inhibitors, and crosslinking and intercalating agents, classically take a broad-based approach to inhibiting the elongation step of DNA replication. This strategy has led to successful treatment outcomes, but off-target effects can lead to dose-limiting toxicity. Cdc7 is a serine/threonine protein kinase essential for the initiation step of DNA replication during the synthesis (S) phase.
Licensee has capabilities in the development of oncology products.
IPSCIO Record ID: 299247
— an exclusive license, with right to sublicense through one or more tiers, under the Licensed Patent Rights to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported Products in the Field.
— an exclusive license, with right to sublicense through one or more tiers, under the Know-How, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported Products in the Field and a nonexclusive license to any other know-how existing on the Closing Date and provided to Licensee which is useful to develop or commercialize the Products in the Field.
The Assigned Patent Rights and Licensed Patent Rights include any prodrug or any hydrate, solvate, conjugate, salt, ester, stereoisomer or polymorph of such compound or prodrug.
— the treatment, topically or systemically, of diseases of the cervix or vaginal tract caused by human papilloma virus (HPV) infection, including cervical high risk·HPV infection and cervical dysplasia, and the treatment of cervical malignancy by topical application to the cervix, but not including systemic treatments of cervical malignancy;
— any use of imiquimod, 848 (resiquimod}, 850 (sotirimod), and the alkyl ureas S-32913 and S-33005, including any acid, ester, salt, amide, prodrug, polymorph, enantiomer or isomer thereof, and any pharmaceutical product containing such compounds, in the Topical Field, which means the treatment, mitigation, or prevention of a disease or condition by topical application (e.g., dermatological, pulmonary or vaginal) of the drug to the skin or mucosa (e.g., bronchialand vaginal tissue) of a patient by, for example, but not limited to, gels, creams, ointments, foams, lotions, salves, roll-ons, powders, sprays, or inhalants, like aerosols such as for asthma and allergic rhinitis;
— marketing the 3MIRM Compounds 852 (N-[4-(4-amino-2-ethyl-1H:imidazo[4;5 c]quinoliri-1-yl)butyl]methanesulfonamide) and/or 854 (N-{2-[4-amino-2 ( ethoxymethyl)-1 H-imidazo[ 4, 5-c]quinolin-1-yl]-1 , 1-d imethylethyl}methanesulfonamide) (including any acid, ester, salt, amide, pro-drug, polymorph, enantiomer or isomer thereof, and.any pharmaceutical product containing such compounds) for the indications of genital warts, common warts, basal cell carcinoma, actinic keratosis, tattoo removal, or photoaging; and
— any use of the 3M Compounds as a Vaccine Adjuvant.
IPSCIO Record ID: 266704
Licensed Compounds shall mean those certain Licensor compounds currently known as: M_-4827 with the following chemical name: 2 [4 (3S) 3 PIPERIDINYLPHENYL] 2H INDAZOLE 7 CARBOXAMIDE and M_-2512 with the following chemical name: 6 (3 [(4 CYCLOPENTYL 3 OXYPIPERAZIN 1 XL)CARBONYL] 4 FLUOROBENZYL] 4,5 DIMETHYLPYRIDAZIN 3(21-l) ONE], and with respect to both, shall include any pharmaceutically acceptable salt, polymorph, crystal form, prodrug or solvate thereof that but for the license granted, would infringe the Compound Patent Rights.
M_-4827, also known as Niraparib, is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor in cancer patients as a monotherapy.
M_-2512 is the backup PARP inhibitor compound.
IPSCIO Record ID: 263778
Licensor grants a co-exclusive license under the Licensors Licensed Know-How to clinically develop, make, have made, use, sell, offer for sale and import Co-Developed Products in the U.S.
Licensor grants a co-exclusive license under the Licensors Licensed Patents to clinically develop, make, have made, use, sell, offer for sale and import Co-Developed Products in the U.S.
Licensor grants an exclusive, subject to Licensors right to conduct Licensor Clinical Trials and work under the Backup Programs pursuant to this Agreement, license under the Licensor Licensed Know-How to clinically develop, make, have made, use, sell, offer for sale and import: Royalty-Bearing Products in the U.S.; and Products in the Royalty Territory.
Licensor grants an exclusive, subject to Licensors right to conduct Licensor Clinical Trials and work under the Backup Programs pursuant to this Agreement, license under the Licensor Licensed Patents to clinically develop, make, have made, use, sell, offer for sale and import: Royalty-Bearing Products in the U.S.; and Products in the Royalty Territory.
Licensor will grant a non-exclusive license to use such Licensor Marks solely in connection with the Commercialization of the Products in the Territory, the Trademark License Agreement.
Product means any therapeutic or prophylactic product that contains or comprises a Collaboration Compound. The Collaboration Compounds means: XL184; and XL281.
XL184 means: the small molecule compound with Licensor identifier 02977184; the small molecule compounds listed in the Letter Agreement; any Program Backups to 02977184; and any isomer, racemate, salt, solvate, hydrate, metabolite, conjugate, ester, or prodrug of the compound.
XL281 means: the small molecule compound with Licensor identifier 03832819; the small molecule compounds listed in the Letter Agreement; any Program Backups to 03832819; and any isomer, racemate, salt, solvate, hydrate, metabolite, conjugate, ester, or prodrug of the compound.
XL184 provides a novel approach to the treatment of a variety of solid tumors where signaling through MET, VEGFR2 or RET plays an important role in dysregulated tumor growth and progression. XL184 has recently begun a Phase III clinical trials in medullary thyroid cancer, a disease in which RET mutations are found in a large proportion of patients. In addition, clinical trials to exploit the MET and VEGFR2 targeting of XL 184 are ongoing in patients with non-small cell lung cancer and glioblastoma. Preclinically, XL184 also exhibits inhibitory activity for .MET and VEGFR2 in a variety of breast, colon and brain tumor models.
XL28 l is a novel small molecule designed to selectively inhibit RAF kinase, which lies immediately downstream of RAS and is a key component of the RAS/RAF/MEK/ERK kinase signaling pathway. The RAS/RAF/MEK/ERK pathway plays a key role in the transmission of growth-promoting signals downstream of receptor tyrosine kinases. Dysregulation of this pathway plays a pivotal role in the progression of many human tumors, and inhibition of the pathway may be useful in the treatment of cancer. Phase I trials with this molecule are underway in order to select a dose and schedule for Phase II disease-directed trials.
IPSCIO Record ID: 289175
Active Compound shall mean a Compound that modulates a Target, the mechanism of which is a binding interaction with a Target, having a level of activity against a Target, expressed as an IC50, that is – less than forty (40) nanomolar- as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan; and a Compound that modulates at least two of the following receptors: TrkA, TrkB or TrkC, the mechanism of which is a binding interaction with the applicable Trk receptor, having a level of activity against the applicable Trk receptor, expressed as an ICso, that is less than forty (40) nanomolar as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan.
Clinical Candidate shall mean, with respect to each Target or Trk, any Active Compound that meets the Clinical Candidate Criteria set forth in the Discovery Plan.
Compound shall mean any one or more chemical entity(ies) made and tested against Trk in the course of Licensors pan-Trk program prior to the Effective Date, or synthesized by Licensor in the course of performing or in connection with the Discovery Program, in each case together with any salt, hydrate, solvate, clathrate, polymorph or isomer thereof.
Product shall mean any pharmaceutical product incorporating as an active ingredient an Active Compound.
Trk shall mean the Trk family of receptors: TrkA, Tr kB and TrkC.
— TrkA shall mean the protein known as UniProtKB/Swiss-Prot # P04629.
— TrkB shall mean the protein known as UniProtKB/Swiss-Prot # Q16620.
— TrkC shall mean the protein known as UniProtKB/Swiss-Prot # Q16288.
The Targets are:
— The protein family commonly known as Firbroblast Growth Factor Receptors (FGFR),
— The protein commonly known as [p70S6 Kinase], identified with the following SwissProt entries:
a) Ribosomal protein S6 kinase beta-1 (P23443)
b) Ribosomal rotein S6 kinase beta-2 (Q9UBS0]— The protein commonly known as Telomerase reverse transcriptase, identified with the following SwissProt entries:
a) Telomerase reverse transcriptase (014746)
b) Telomerase protein component 1 (Q99973)
Licensee possesses pharmaceutical research, development and commercialization capabilities, as well as proprietary technology in the field of cancer treatment.
IPSCIO Record ID: 245935
Licensed Patents:
6,613,753 – Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
6,982,253 – Liquid formulation of decitabine and use of the same
6,998,391 – Method for treating diseases associated with abnormal kinase activity
6,905,669 – Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
DACOGEN Trademark shall me mean the DACOGEN mark and accompanying logos associated with it.
Products shall mean (i) the product containing Decitabine which is the subject of Licensor’s NDA No. 21-790 as of the date of signing of this Agreement; and (ii) any other pharmaceutical product containing as an active ingredient Decitabine.
Decitabine shall mean the compound identified below, and all stereoisomers, salts and polymorphs of the compound identified below. Esters and acids of the compound identified below shall be included to the extent they constitute the same active ingredient as the compound identified below.
Decitabine:
C8H12N404
Exact Mass: 228.086
Mol. Wt.: 228.205
Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.
IPSCIO Record ID: 245713
Licensed Patent: 8981089B2 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS. Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
Licensed Product means any product or service incorporating Milciclib as active ingredient for the treatment of metastatic HCC, an aggressive type of liver cancer.
IPSCIO Record ID: 87663
Also upon Licensee’s payment of the Option Exercise Fee, Licensor grants an exclusive license, with the right to sublicense through multiple tiers, under the Intellectual Property to research, develop, make, have made, use, import, export, offer for sale, sell and otherwise commercialize licensed compounds and products.
The Licensed Compound means CG’806 or any other compound whose composition, manufacture or use is claimed by a claim in the patents and patent applications and that relates to the composition, method of use, mechanism of action or method of manufacture of any inhibitor of any kinase within the BTK family of kinases. The US patent application is 61/746,980 2,3-DihydroI-Isoindol-1-One Derivatives and methods of use thereof as Bruton’s Tyrosine Kinase or BTK inhibitor. The BTK family of kinases are cancer therapies, including its proprietary compound referred to as CG026806 (“CG’806â€).
IPSCIO Record ID: 203313
'Patent Rights' shall mean: (i) U.S. Patent Nos. 5,502,047, 5,643,897, 6,211,229 and 6,344,487
IPSCIO Record ID: 183244
This agreement is for the pharmaceutical industry, excluding oncology use.
IPSCIO Record ID: 291166
Licenosr hereby grants Licensee an exclusive (even as to Licensee), royalty-bearing license in the Territory, without the right to grant sublicenses, under all of Licensors rights under all JAK-3 Joint Patent Rights to make, have made, use, offer to sell, sell, import, export and otherwise Develop and Commercialize all JAK-3 Kinase Inhibitors having as their primary mechanism of action JAK-3 Kinase Inhibitory Activity (and products containing any such JAK-3 Kinase Inhibitors) in the Licensee Field during the term.
Licensor hereby grants Licensee an exclusive (even as to Licensor), royalty-beariing license in the Territory, with the right to grant sublicenses, (Sublicensing), under the Licensor IP and Licensors rights, title and interests in the Joint IP to make, have made, use, offer to sell, sell, import, export and otherwise Develop and Commercialize Licensee Available Compounds (and any Licensee Products containing any such Licensee Available Compounds) in the Licensee Field.
JAK-3 Kinase Inhibitory Activity means, when used to describe a compound, that the compound binds to the protein tyrosine kinase enzyme known as Janus Activating Kinase 3 (JAK-3).
JAK-3 Joint Patent Right means Joint Patent Rights that claim inventions that are reasonably necessary to make, have made, use, offer to sell, sell, import, export and otherwise Develop and Commercialize Agreement Compounds.
Licensor Patent Right means all Patent Rights Controlled by Licensor as of the Effective Date or during the term, as are reasonably necessary to Develop, make, have made, use, import or export Agreement Compounds, or to make, have made, use. offer to sell, sell, import, export or otherwise Commercialize Products based thereon; provided, however, that if a Third Party becomes an Affiliate of Licensor pursuant to a Change of Control Transaction as a result of which such Third Party is able to elect a majority of the members of the board of directors of Licensor (or its successor company) or any of its 'controlling Affiliates' (Change of Control Transaction), 'Licensor Patent Rights' not include any Patent Rights that were Controlled by such Third Party (and not by Licensor) prior to the completion of such Change of Control Transaction. It is understood that Licensor Patent Rights shall not include any intellectual property owned or licensed by Licensor relating to (i) the creation or use of encoding technology for combinatorial libraries, (ii) tag and/or marker compound engineering, encoding or decoding, or (iii) high throughput screening assays.
Licensor Available Compound means:
(a) any Licensor Compound or Collaboration Compound selected by Licensor for Development (Compound Selection) and for which Licensor is fulfilling the diligence obligations required (Compound Selection); and (b) any Licensor Compound or Collaboration Compound with respect to which Licensor has undertaken Development in the Licensee Field if permitted and for which Licensor is fulfilling the diligence obligations required (Compound Selection).
Patent Rights means any and all (a) patents, (b) pending patent applications, including, without limitation, all provisional applications, substitutions, continuations, continuations-in-part, divisions, renewals, and all patents granted thereon, (c) all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including, without limitation, supplementary protection certificates or the equivalent thereof (d) inventor’s certificates, and (e) all United States and foreign counterparts of any of the foregoing.
Product(s) means Licensor Product(s) or Licensee Product(s), as the case may be.
Licensor Product means a pharmaceutical preparation containing a Licensor Available Compound. For purposes of clarity, any pharmaceutical preparations containing the same Licensor Available Compound will be deemed to be the same Licensor Product.
Licensee Product means a pharmaceutical preparation containing a Licensee Available Compound. For purposes of clarity, any pharmaceutical preparations containing the same Licensee Available Compound will be deemed to be the same Licensee Product. For the avoidance of doubt, a Licensee Product will not be considered to be separate, distinct and different from another Licensee Product solely on the basis of its use for a different indication, method of production or manufacture, method of delivery or dosage level.
Licensee Field means all human therapeutic and prophylactic uses of a Product other than uses included within the Licensor Field.
IPSCIO Record ID: 27879
IPSCIO Record ID: 273392
Licensor hereby agrees to grant and does grant Licensee a non-exclusive worldwide license, with rights to sublicense, under any Licensor Consulting IP, to develop, make, use, have made, and sell Development Candidates in the Licensee Development Field.
Licensor will and hereby does grant to Licensee a non-exclusive worldwide license, with the right to sublicense, under Licensor’s interest in such invention, patent or patent application, to develop, make, use, have made and sell Development Candidates in the Licensee Development Field.
Licensor Research Tool Patents means the U.S. Patents listed and any related foreign patents and patent applications related thereto, including (a) any continuation, continuation-in-part, divisional, resissue, reexamination or extension thereof, (b) any patent issued from any such applications, and (c) all inventions claimed in any of the foregoing.
U.S. Patent No 6,632,830 – ACE-2 inhibiting compounds and methods of use thereof
U.S. Patent No 7,045,532 – ACE-2 modulating compounds and methods of use thereof
US Patent No 6,194,556 – The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.
US Patent No 6,989,363 – Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US Patent No 6,610,497 – Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US Patent No 6,884,771 – Angiotensin converting enzyme homolog and uses therefor
US Patent Application No. 11/059218
US Patent Application No. 10/659000
Development Candidate means any Compound or Biotherapeutic Compound that is developed by Licensee alone or by a third party (with or without the participation of Licensee) under a Development Arrangement.
Compound means (a) MLN 4760; (b) any other compound covered by a Valid Claim under Licensor Patent Rights; (c) any compound made under Licensee’s development hereunder; (d) any metabolite, ester, salt, hydrate, solvate, polymorph, stereoisomer, prodrug, or formulation of the foregoing described in (a), (b), or (c); and (e) any product that has as an active ingredient (a), (b), (c), or (d).
MLN 4760 means the chemical compound known as MLN 4760 and more fully described as (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylamino]-4-methylpentanoic acid.
Biotherapeutic Compound means any molecule that has a molecular weight in excess of 1500 Daltons and that is covered by, or is developed through activities covered by, Licensor Research Tool Patents.
Type 1 Diabetes means insulin-dependent diabetes mellitus as diagnosed according to criteria published in the Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (Diabetes Care, Vol. 24, Supp. 1, January 2001) whereby fasting plasma glucose level is greater than or equal to 126 milligrams per deciliter and for which the primary cause is beta-cell destruction.
Type 2 Diabetes non-insulin-dependent diabetes mellitus as diagnosed according to criteria published in the Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (Diabetes Care, Vol. 24, Supp. 1, January 2001) whereby fasting plasma glucose level is greater than or equal to 126 milligrams per deciliter.
Obesity means the condition of excess body fat (adipose tissue), in accordance with the National Institutes of Health Federal Obesity Clinical Guidelines for adults, whereby body mass index calculated by dividing body mass in kilograms by height in meters squared is equal to or greater than twenty-five (25) (for purposes of this definition, Obesity shall include an overweight condition in accordance with the above guidelines and comparable obesity and overweight condition in children).
Oncology Diseases means the prevention, diagnosis, and treatment of oncological diseases (including modulation of tumor angiogenesis).
IPSCIO Record ID: 239024
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.
IPSCIO Record ID: 237253
Licensor grants an exclusive worldwide license under the Licensor Technology, with no right to sublicense, to the extent useful to permit Licensee to use Biomarkers to monitor the effectiveness of the Compound in the Field, including in human subjects, solely in connection with research and/or development of Drug Products. Licensor agrees that it shall negotiate in good faith with Licensee to reach agreement on a license to diagnostic products incorporating such Biomarkers for use solely in connection with the administration of the Drug Product in the Field. Licensor reserves all rights to Biomarkers and the use thereof for all purposes outside the Field.
This agreement also includes a non-exclusive grant back to Licensor.
The Compound shall mean VX-944 and and any of its hydrates, salts, stereoisomers, polymorphs, prodrugs or metabolites.
IMPDH shall mean Inosine 5 -monophosphate dehydrogenase.
Drug Product shall mean any pharmaceutical preparation in finished dosage form containing the Compound for administration to human patients for any and all uses in the Field.
VX-944 is a small molecule, selective, uncompetitive novel inhibitor directed against human IMPDH enzyme. IMPDH inhibitors have been demonstrated to induce growth arrest, and extensively investigated as immunosuppressants. Here we show that VX-944 inhibits growth of human multiple myeloma (MM) cell lines, including those resistant to conventional agents, via induction of apoptosis and S phase arrest in vitro.
IPSCIO Record ID: 245948
Licensor hereby grants to Licensee an exclusive right and license, with the right to sublicense, under the Licensor Patent Rights A and Licensor Patent Rights B and the Licensor Know-How to make and have made, use and have used the Compound in the Licensee Territory within the Field.
Licensor hereby grants to Licensee an exclusive right and license, with the right to sublicense, under the Licensor Improvements to make, have made, use, have used, sell, have sold, offer for sale and distribute the Product in the Licensee Territory within the Field.
Patent Rights A:
Appl # – Kind
#28201 – Product
#79560 – Process (oxidization)
#09/025752 – Formulation (liposome)
#09/466903 – Process (isomerization)
Licensor Patent Rights B shall mean the Patent Rights in the Field owned or Controlled by Licensor as of the Effective Date as listed, and any additional Patent Rights in the Field to which Licensor acquires rights during the Term, which pertain in any way to the subject matter claimed or disclosed in the Patent Rights listed
Patent Rights B:
Appl # – Kind
10/018349 – Leakage inhibition from liposome
Product shall mean any pharmaceutical product in finished form which contains the Compound as an active pharmaceutical ingredient. For avoidance of doubt, the Combination Product is a Product.
Compound shall mean KW-2401 (UCN-01), the chemical structure.
KRX-0601, also known as UCN-01, is a synthetic derivative of staurosporine with antineoplastic activity. Staurosporine is a cell permeable alkaloid isolated from Streptomyces staurosporeus exhibiting anti-cancer activity. Staurosporine is a potent, non-selective inhibitor of protein kinases, including protein kinase C.
IPSCIO Record ID: 283332
Licensee acquired all rights, including composition of matter patents (the “PKCd Patentsâ€), and preclinical study data to a novel therapeutic technology platform, known as protein kinase C delta (PKCd) inhibitors, which represents a unique, highly-targeted approach to treat cancer and to boost the immune system.
